Antiviral β-L-nucleosides specific for hepatitis B virus infection

Antiviral Chemistry and Chemotherapy, Supplement

Volumn 12, Issue 1, 2001, Pages 119-129

  Standring, D N ^a   Bridges, E G ^a   Placidi, L ^a   Faraj, A ^a   Loi, A G ^a   Pierra, C ^a   Dukhan, D ^a   Gosselin, G ^a   Imbach, J L ^a   Hernandez, B ^a   Juodawlkis, A ^a   Tennant, B ^a   Korba, B ^a   Cote, P ^a   Cretton Scott, E ^a   Schinazi, R F ^a   Myers, M ^a   Bryant, M L ^a   Sommadossi, J P ^a  

^a Novirio Pharmaceuticals   (United States)

Author keywords

Clinical trials; IND; LdA; LdC; LdT; Metabolism; Pharmacokinetics; Safety; Woodchuck hepatitis virus

Indexed keywords

2' DEOXYNUCLEOSIDE; DEOXYADENOSINE; DEOXYCYTIDINE; THYMIDINE DERIVATIVE;

CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HEPATITIS B; HEPATITIS B VIRUS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPATITIS B; HUMANS; MICROBIAL SENSITIVITY TESTS; NUCLEOSIDES;

ANAS SP.; DNA VIRUSES; HEPADNAVIRIDAE; HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS B VIRUS;

EID: 0034808628     PISSN: 13502816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Synthesis of potential prodrugs of β-L-dC, a potent and selective anti-HBV agent
2. Anti-human immunodeficiency and anti-hepatitis B virus activities of β-L-2′,3′-dideoxy purine nucleosides
3. Toxicological study of the anti-HBV agent 13-L-2′-deoxythymidine
4. Toxicological evaluation of the anti-HBV agent β-L-deoxythymidine
5. Antiviral L-nucleosides specific for hepatitis B virus infection
6. Antiviral L-nucleosides specific for hepatitis B virus infection
7. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
8. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′- dideoxycytidine
9. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection
10. Pharmacokinetics of β-L-thymidine and β-L-deoxycitidine in woodchucks and monkeys
11. Pharmacokinetics of β-L-2′-deoxycytidine prodrugs in monkeys
12. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranoxyl)-5-iodouracil in human liver cells
13. Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial funtions in HepG2 cells
14. Mitochondrial DNA effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
15. Mitochondrial myopathy caused by long-term zidovudine therapy
16. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
17. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis
18. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection
19. Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5′-triphosphate as substrate
20. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
21. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
22. Enantiomeric 2′,3′-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell culture
23. New unnatural L-nucleoside enantiomers: From their stereoselective synthesis to their biological activities
24. Stavudine: An update of its use in the treatment of HIV infection
25. Synergistic antiviral L-nucleosides specific for hepatitis B virus infection
26. Woodchuck hepatitis virus infection as a model for the development of antiviral therapies against HBV
27. Treatment of chronic woodchuck hepatitis virus infection in the eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans
28. A one-year trial of lamivudine for chronic hepatitis B
29. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondrial
30. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitchondrial structural defects in cultured hepatoblasts
31. Effect of stereoisomerism on the cellular pharmacology of beta- enantiomers of cytidine analogs in HepG2 cells
32. Lamivudine therapy of WHV-infected woodchucks
33. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3′-azido-3′-deoxythymidine (AZT) to 3′-amino3′-deoxythymidine
34. Differential effects of antiretroviral nucleoside analogs on mitochondrial function; dual inhibition of citrate synthase and cytochrome c oxidase by AZT
35. Comparative studies of selected potential prodrugs of β-L-dC, a potent and selective anti-HBV agent
36. Cellular pharmacology of β-L-thymidine (L-dT, NV-02B) and β-L-2′-deoxycytidine (L-dC, NV-02C) in HepG2 cells and primary rat, monkey and human hepatocytes
37. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks
38. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-hydroxymethyl)-1,3-oxatiolan-5-yl]cytosine
39. Stereoisomers of deoxynucleoside 5′-triphosphates as substrates for template-dependent and -independent DNA polymerases
40. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′- dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reyerse transcriptase
41. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells
42. L-thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth
43. The woodchuck in preclinical assessment of therapy for hepatitis B virus infection
44. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
45. Lack of enantiospecificity of human 2′-deoxycytidine kinase: Relevance for the activation of β-L-deoxycytidine analogs as antineoplastic and antiviral agents
46. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)
47. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy